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ABSTRACT
Daptomycin is the ﬁrst of a new class of antibiotics, the cyclic lipopeptides, for which a novel mechanism
of action is hypothesised. Owing to its mode of action, daptomycin is rapidly bactericidal without being
bacteriolytic, is active against static- and growing-phase bacteria, and has a low resistance rate in vitro.
Phase III clinical trials have demonstrated that daptomycin is as effective as standard therapy for the
treatment of complicated skin and soft-tissue infections associated with Gram-positive infections, and
daptomycin-treated patients beneﬁted from a reduced time to clinical resolution. Daptomycin has also
been shown to be as effective as standard therapy in the treatment of bacteraemia associated with
Staphylococcus aureus, with or without endocarditis. These results indicate that daptomycin is a useful
therapeutic option for treating Gram-positive infections, particularly those caused by S. aureus.
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INTRODUCTION
The cyclic lipopeptides are one of the most recent
antibiotic classes with a novel mode of action to
gain marketing approval. Their introduction
comes at a time of growing concern over the
dearth of new antibiotics under development [1].
Daptomycin is the ﬁrst antibiotic in this new class
to acquire marketing approval. It is currently
licensed in the USA for the treatment of compli-
cated skin and skin-structure infections caused by
Gram-positive organisms and bacteraemia, with
or without right-sided endocarditis caused by
Staphylococcus aureus [2]. More recently, it has also
been approved by the European Medicines
Agency for the treatment of complicated skin
and soft-tissue infections (cSSTIs), right-sided
infective endocarditis due to S. aureus bactera-
emia (SAB), and SAB when associated with right-
sided endocarditis or cSSTIs [3].
The magnitude of the healthcare burden asso-
ciated with invasive methicillin-resistant S. aureus
(MRSA) has been quantiﬁed for the US popula-
tion in 2005 as a standardised incidence rate of
31.8 per 100 000 persons, as compared with the
incidence of other important invasive pathogens,
such as Streptococcus pneumoniae or Haemophilus
inﬂuenzae, which ranged from 14.0 per 100 000 to
<1 per 100 000 [4,5]. Moreover, the study showed
that MRSA infections are no longer conﬁned to
healthcare institutions; MRSA strains isolated
from community-acquired infections are becom-
ing increasingly common. In this context, the
activity of daptomycin against both MRSA and
methicillin-susceptible S. aureus (MSSA) makes it
an attractive alternative to standard therapies,
particularly as the incidence of MRSA with
reduced susceptibility to vancomycin—the cur-
rent reference standard for the treatment of
MRSA—is increasing [6,7,8].
The antibacterial activity of daptomycin is
believed to be mediated through depolarisation
of the bacterial cell membrane. Daptomycin
inserts into and irreversibly binds within the
bacterial cell membrane in a calcium-dependent
process [9,10] (Fig. 1). Subsequent oligomerisation
of daptomycin molecules within the membrane
leads to the formation of pores or ion channels,
which allow potassium efﬂux from the bacterial
cytoplasm, thus destroying the ion concentration
gradient [11]. This depolarises the cell membrane
and causes rapid cell death through the inhibition
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of DNA, RNA and protein synthesis [12]. This
mode of action endows daptomycin with a broad
spectrum of activity against Gram-positive bacte-
ria. It is bactericidal without being bacteriolytic, a
feature that contributes to reducing overstimula-
tion of the immune response by bacteria and
prolongation of inﬂammation [13], which can
result in severe inﬂammatory response syndrome
[14,15]. Furthermore, daptomycin is active in both
the static and growth phases of bacteria [16], a
property that is highly unusual [15]. In-vitro
experiments have demonstrated the difﬁculty
with which bacterial resistance to daptomycin
develops [9,10,17], and the novel mechanism of
action of daptomycin means that cross-resistance
is unlikely to develop [18].
In-vitro and in-vivo studies have demonstrated
that daptomycin is more rapidly bactericidal than
vancomycin [19,20]. Clinical trials support these
ﬁndings and demonstrate that daptomycin is a
viable alternative to vancomycin for treating
cSSTIs and SAB; certain study outcomes, e.g.,
duration of effective therapy and time to clinical
resolution, also indicate that daptomycin may
provide advantages over the current standard-of-
care regimens [21,22].
SKIN AND SOFT-TISSUE
INFECTIONS
The term SSTI describes a wide variety of infec-
tions affecting the epidermis, dermis and subcu-
taneous tissues, and these can be classiﬁed
according to four levels of severity and the
presence of co-morbidities [23]. In general, class 1
represents uncomplicated SSTIs (e.g., boils and
simple abscesses), whereas classes 2–4 encompass
cSSTIs, i.e., SSTIs complicated by co-morbidities
and ⁄ or systemic involvement on a scale of
increasing severity [24] (e.g., infected ulcers and
necrotising fasciitis). Patients with cSSTIs present
with a spectrum of clinical manifestation, depend-
ing on the depth of soft-tissue involvement, the
pathogen(s) present and the degree of systemic
compromise. Diagnosing cSSTIs is not straight-
forward, because there are no speciﬁc symptoms
that deﬁne cSSTIs. Infections can be asymptom-
atic during the initial stages and it can be difﬁcult
to differentiate between uncomplicated and com-
plicated infections [23]. Nonetheless, several pre-
disposing factors for the development of cSSTIs
have been identiﬁed [14] (Table 1).
Clinical studies of daptomycin in skin and
soft-tissue infections
Daptomycin received marketing authorisation in
the USA and the EU for the treatment of cSSTIs on
the basis of the ﬁndings of two phase III
international, multicentre, randomised, investiga-
tor-blinded trials (DAP-SST-98-01 and DAP-SST-
99-01) conducted between 1999 and 2001 [21]. The
trials compared daptomycin (4 mg ⁄ kg intrave-
nously once daily for 7–14 days) with either
vancomycin (1 g intravenously every 12 h) or
penicillinase-resistant semi-synthetic penicillins
(nafcillin, cloxacillin, ﬂucloxacillin or oxacillin;
4–12 g intravenously once daily) in the treatment
of 1092 patients (total sum of both trials) with
cSSTIs due to Gram-positive bacteria, and who
required hospitalisation. Investigators assigned
the comparator regimen depending on baseline
diagnosis. Patients were then randomised 1:1 to
receive daptomycin (n = 534) or the pre-assigned
comparator regimen (n = 558) (Fig. 2). The pri-
mary outcomes were based on clinical and micro-
biological assessments performed at baseline and
Fig. 1. Mode of action of daptomycin. Daptomycin inserts
into the bacterial membrane in a calcium-dependent
fashion. Oligomerisation and disruption of the bacterial
membrane follows, and leads to depolarisation of the
bacterial membrane through release of ions, which in turn
leads to the disruption of intracellular processes. From
Silverman et al. [10]
Table 1. Predisposing factors for developing skin and
soft-tissue infections [14]
Advanced age
Reduced arterial perfusion
Neuropathy
Diabetes mellitus
Chronic venous insufﬁciency
Obesity
Malnutrition
Compromised immune function
Disruption of the skin
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6–20 days after administration of the last treat-
ment dose (for the regulatory dossier prepared for
the European Medicines Agency, analyses were
based on a test of cure assessed at 7–13 days after
the ﬁnal treatment [25]). Clinical success was
deﬁned as ‘resolution of signs and symptoms
such that no further antibiotic therapy was
required’ at the test of cure, and further evalua-
tion was carried out at a post-study visit 20–
28 days after the ﬁnal dose, to determine whether
there was a clinical relapse or new infection.
Patients were considered to be treatment failures
if an inadequate response to therapy was ob-
served at any stage of the investigation.
Diagnoses in the intention-to-treat (ITT) popu-
lation across both arms of the study included
major abscesses (26% in the daptomycin treat-
ment arm and 22% in the comparator arm),
wound infections (42% and 46%, respectively),
diabetic ulcer infections (11% and 13%, respec-
tively), and non-diabetic ulcer infections (13%
and 13%, respectively). S. aureus was the Gram-
positive pathogen most frequently cultured from
the primary infection site (71% in the daptomycin
arm and 69% in the comparator arm); the major-
ity of these were methicillin-susceptible (54% and
51% of all isolates in each arm, respectively).
Several patients were infected with multiple
organisms; the most frequently occurring combi-
nation was S. aureus and Streptococcus pyogenes.
No vancomycin-resistant enterococcal infections
were detected in the studies.
Daptomycin was deemed to be non-inferior to
the comparator regimens, as measured by the
clinical success rate in all analysed patient pop-
ulations (ITT; modiﬁed ITT; clinically evaluable;
microbiologically evaluable) (Fig. 3). Although
differences were observed in clinical success rates
stratiﬁed by organism, these rates were similar for
daptomycin and the comparator regimens. Sub-
analyses indicated no signiﬁcant differences
between the two arms in the treatment of MSSA
and MRSA in the microbiologically evaluable
population. The success rate was lower in both
the daptomycin and comparator regimen arms for
MRSA (75.0% and 69.4%, respectively) than for
MSSA (85.9% and 87.0%, respectively). A possi-
ble explanation for the reduced success of all
treatments against MRSA is a higher incidence of
co-morbidities in the MRSA population (author’s
unpublished observations).
A signiﬁcant difference in favour of daptomy-
cin was observed for the duration of therapy
among patients who were successfully treated
with intravenous therapy alone. A total of 63%
of patients receiving daptomycin required only
4–7 days of therapy, as compared with 33% in
the comparator arm (p < 0.0001). This could be
attributable to the increased in-vivo bactericidal
activity of daptomycin as compared with vanco-
mycin, which has been demonstrated in mice
but has yet to be shown against other compar-
ator agents in vivo [19]. An alternative, and
perhaps more likely, explanation for this differ-
ence is that reduced lysis of the invading
bacteria, as they are killed, results in reduced
immunopathology [13].
The safety proﬁle for daptomycin was similar to
that of the comparator agents, with no signiﬁcant
Investigator assigns comparator agent
Penicillinase-resistant 
penicillin (PRP)
Vancomycin
(VAN)
Daptomycin Comparator(VAN)Daptomycin
Comparator
(PRP)
Randomisation to treatment group
Fig. 2. Study design of DAP-SST-98-01 and DAP-SST-99-
01 [21].
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Fig. 3. Clinical success rates (deﬁned as cure or improve-
ment sufﬁcient to warrant discontinuing antibiotic
treatment) of daptomycin and comparators in studies
DAP-SST-98-01 and DAP-SST-99-01 [21]. Ninety-ﬁve per-
cent conﬁdence intervals are given for the rate in the
comparator group minus that for the daptomycin group.
ITT, intention to treat; mITT, modiﬁed intention to treat;
CE, clinically evaluable; ME, microbiologically evaluable.
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differences being observed in the frequency,
distribution and severity of adverse events. Dap-
tomycin has been reported to have the potential
for causing muscle toxicity [26]; however, close
monitoring of creatine phosphokinase (CPK) lev-
els did not reveal a signiﬁcant difference between
daptomycin-treated (2.8%) and comparator-trea-
ted (1.8%) patients in terms of CPK elevations,
and there was no signiﬁcant difference in the rate
of musculoskeletal adverse events [2]. Further-
more, among patients with elevated CPK levels
prior to commencing therapy, the frequency with
which CPK levels returned to normal was greater
in the daptomycin arm [2].
Overall, these clinical trials demonstrated that
daptomycin, given at 4 mg ⁄ kg once daily, is as
safe and effective as standard therapy for the
treatment of cSSTIs caused by Gram-positive
pathogens.
SAB AND INFECTIVE
ENDOCARDITIS
Bacteraemia is deﬁned as the presence of culti-
vatable bacterial organisms in the bloodstream,
which may be transient and inconsequential,
intermittent or persistent [27]. Intermittent bac-
teraemia suggests that the bacteria originate from
an extravascular site, entering the bloodstream
via the lymphatic system, whereas persistent
bacteraemia suggests an intravascular source
(e.g., endocarditis) [28]. Bacteraemia can be clin-
ically signiﬁcant because of the risk of complica-
tions and the potential to progress to sepsis,
deﬁned as the presence of clinical signs and
symptoms of infection, i.e. a generalised inﬂam-
matory reaction, in addition to the presence of
bacteraemia [28]. This reaction is characterised by
numerous symptoms, e.g., fever and increased
heart rate, respiratory rate and white blood cell
counts. Patients are deﬁned as having severe
sepsis if there are concomitant signs of hypoten-
sion, hypoperfusion or dysfunction of organs
distant from the site of infection [27].
S. aureus is a signiﬁcant cause of bacteraemia
in both nosocomial and community settings [29],
and is associated with complications that include
deep tissue abscesses, osteomyelitis and infective
endocarditis, particularly in bacteraemic
episodes of more than 48 h [30,31]. The rise of
antibiotic-resistant strains of S. aureus impacts on
both the prognosis and treatment of SAB; meta-
analyses have shown that MRSA bacteraemia is
associated with increased mortality rates, as
compared with MSSA bacteraemia [32,33]. The
explanation for this difference goes beyond the
presence of excess co-morbidities in the MRSA
patients, because meta-analyses that have con-
trolled for underlying co-morbidities still indi-
cate an increased mortality rate [32–34]. With
respect to hospital-acquired MRSA, this higher
mortality rate is not due to any known difference
in virulence between MRSA (as reported during
the time of the studies included in the meta-
analyses) and MSSA [32]. Findings from a
retrospective cohort analysis suggest that
delayed treatment signiﬁcantly increases the rate
of mortality and duration of stay [35], while
another study has shown that slight decreases
in vancomycin susceptibility to MRSA (MIC
‡1.0 mg ⁄L) in vitro can affect the clinical suscep-
tibility of MRSA to vancomycin [36]. Therefore,
the differences observed in mortality rates
between MRSA and MSSA bacteraemia are more
likely to be due to delayed treatment, ineffective
empirical therapy, and the decreased efﬁcacy of
vancomycin as a targeted therapy [31,35].
Treatment options for MSSA and MRSA bac-
teraemia and infective endocarditis are dependent
on the susceptibility of the isolate to antibiotics
[31]. At present, MRSA infection is generally
treated with vancomycin, whereas, depending on
the results of in-vitro susceptibility tests, penicil-
linase-resistant penicillins and cephalosporin are
the traditional options for MSSA infections. How-
ever, analyses of the susceptibility of strains of
S. aureus to vancomycin indicate that susceptibil-
ity is decreasing in some geographical areas [8],
which has resulted in decreased rates of treatment
success [36]. New antibiotics, such as daptomycin,
represent a potential solution to this problem. For
a more detailed discussion of vancomycin resis-
tance and its implications, the reader is referred to
the accompanying article by Jones in this supple-
ment.
An in-vitro pharmacodynamic model with sim-
ulated endocardial vegetations demonstrated the
potent bactericidal activity of daptomycin against
high-inoculum MRSA [16]. Daptomycin 6 mg ⁄ kg
once-daily (simulating a human therapeutic dose
regimen) achieved 99.9% kill (deﬁned as a
‡3 log10 CFU ⁄ g reduction in colony count from
the initial inoculum) of high-inoculum MRSA
within 36 h, and maintained this bactericidal
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activity for 96 h (Fig. 4). In contrast, vancomycin
1 g every 12 h failed to achieve bactericidal
activity against MRSA at any time-point. The
addition of a single 5 mg ⁄kg dose of gentamicin
to vancomycin 5 mg ⁄kg resulted in 99.9% kill at
32 h for MRSA.
The efﬁcacy of daptomycin in the treatment of
SAB, with or without endocarditis, has been
investigated in an open-label trial of 246 patients
randomised to receive either daptomycin
6 mg ⁄ kg once-daily or an initial low dose of
gentamicin plus an anti-staphylococcal penicillin
or vancomycin [22]. The primary outcome was
assessed in the modiﬁed ITT population (all
randomised patients who received at least one
dose of study medication, except for those
enrolled with suspected left-sided endocarditis
before a protocol amendment allowed the inclu-
sion) 42 days after the end of treatment. At this
time, clinical failure included microbiological
failure, death, failure to obtain blood culture at
the 6-week post-therapy test of cure visit, receipt
of potentially effective non-study antibiotics
before the test of cure, and premature discontin-
uation. Daptomycin treatment was found to be
non-inferior to standard therapy. The clinical
success rate in patients with SAB (with or without
infective endocarditis) was 44.2% for daptomycin
therapy as compared with 41.7% for standard
therapy (absolute difference 2.4%; 95% CI – 10.2
to 15.1).
Daptomycin had a success rate in the treatment
of MSSA bacteraemia equivalent to comparator
treatments (vancomycin plus gentamicin, or semi-
synthetic penicillin plus gentamicin) [22] (Fig. 5).
However, in a pre-speciﬁed analysis of patients
infected with MRSA, daptomycin had a higher
success rate (44.4%) than vancomycin plus genta-
micin (32.6%) in the treatment of MRSA bactera-
emia (Rehm et al., Abstract book of the 44thAnnual
Meeting of the IDSA, 12–15 October 2006, p. 56).
Although these data were not statistically signiﬁ-
cant, the trend in favour of daptomycin was
observed across all patient subgroups. These
results demonstrate that daptomycin is as effective
as comparator agents in treating MSSA bactera-
emia and, comparedwith vancomycin, might have
increased efﬁcacy for treating MRSA bacteraemia.
CONCLUSION
Daptomycin represents the ﬁrst of a new class of
antibiotics, the cyclic lipopeptides, and has a
novel mechanism of action. Daptomycin has
broad bactericidal activity against Gram-positive
pathogens, including MSSA and MRSA. Phase III
clinical trial data show that the efﬁcacy and safety
of daptomycin are similar to those of vancomycin
and other standard therapies for the treatment of
cSSTIs; however, results from these trials indicate
that daptomycin therapy, as compared with
standard therapies, might result in more rapid
clinical resolution of infections [21].
S. aureus is a signiﬁcant cause of bacteraemia
and infective endocarditis. Success with vanco-
mycin, the reference-standard treatment, is
declining in some areas because of the decreasing
susceptibility of S. aureus strains. Daptomycin has
Fig. 4. Comparison of activities of daptomycin (at 6 and
8 mg ⁄ kg), and vancomycin alone and in combination with
a single dose of gentamicin, against methicillin-resistant
Stapylococcus aureus. D6, daptomycin 6 mg ⁄ kg once daily;
D8, daptomycin 8 mg ⁄ kg once daily; V, vancomycin given
every 12 h; G5 · 1, gentamicin in one 5 mg ⁄kg dose; GC,
growth control. From Tsuji [16].
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been shown to be similar to standard therapies for
the treatment of infective endocarditis caused by
MSSA, whereas sub-analyses indicate that dapto-
mycin may be more effective than standard
therapies for treating bacteraemia caused by
MRSA.
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